Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
Elucidata is a company oriented around supporting scientific research, emphasizing making users' research more efficient and respecting the scientific method. The available page content does not describe its concrete products or offerings in detail.
2 investors
Elytron is a deeptech company that discovers and develops biological assetsβusing AI, multi-omics and functional testingβto turn microorganisms into industrial products. It serves industrial clients at various stages, from candidate discovery to deployment and process monitoring, with initial validation in agriculture and active operations in Argentina and Brazil.
2 investors
Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, including ecopipam, an investigational dopamine D1 receptor antagonist for pediatric Tourette syndrome. The company, created by Paragon Biosciences, advanced the asset through clinical development and was acquired by Teva Pharmaceutical Industries in 2026.
2 investors
Emedgene provides genomic interpretation software that uses explainable AI and automation to prioritize, interpret, curate, and classify genetic variants from sequencing (WGS, WES, panels) and microarray data. It serves clinical and research genetics laboratories conducting rare disease research, hereditary risk assessment, carrier screening, and similar genetic disease testing workflows, and integrates with Illumina's DRAGEN secondary analysis.
2 investors
Emergent BioSolutions is a public health company that develops, manufactures, and supplies medical countermeasures for national security and preparedness, along with commercialized products addressing threats such as the opioid epidemic. It also provides in-house development and manufacturing support to biopharma innovators, governments, and non-governmental organizations.
2 investors
Emergo Therapeutics develops drugs designed to modulate inflammatory responses by reducing the production and secretion of inflammatory cytokines, targeting damaging symptoms across a range of diseases. Its pharmaceutical programs address acute and chronic conditions including flu/influenza-like illness and Long COVID, with clinical trials conducted in coordination with the FDA.
2 investors
Scene Health (formerly emocha) offers a medication adherence platform called MedEngagement that uses asynchronous video Directly Observed Therapy (DOT) and a care team to help patients take medications correctly for chronic and infectious conditions. It serves health plans, public health departments, clinical trial sponsors, and CROs to improve clinical outcomes, adherence rates, and trial efficiency.
2 investors
Empirical Bio builds machine learning software that predicts and optimizes the structure of enzymes and other biomolecules. Biotech research teams use it to narrow down candidates computationally before moving to the bench, which reduces the number of laboratory testing cycles required.
2 investors
ENA Respiratory develops and brings respiratory treatments to market across the US and other regions. The company operates at the intersection of pharmaceutical product development and clinical innovation, with deep expertise in bringing early-stage respiratory therapies through development and regulatory approval.
2 investors
ENB Therapeutics develops small molecules targeting the endothelin B receptor (ETBR) in the tumor microenvironment to treat drug-resistant cancers by restoring immune cell infiltration and promoting tertiary lymphoid organ formation. Its preclinical therapies target cancers including melanoma, glioblastoma, squamous cell carcinoma, bladder cancer, and ovarian cancer.
2 investors
Encapsulate builds automated tumor-on-a-chip systems that test microtumors derived from patient biopsies against treatment regimens to predict how individual cancer patients will respond, delivering personalized insights in under seven days. It serves oncologists, pharmaceutical companies, and cancer researchers, drawing on a patient biobank for drug testing, patient stratification, and mechanism studies.
2 investors
Endless is an online workspace for content creators that brings AI-assisted tools such as chat, transcript generation, image and video creation, and a social radar into a single platform. It supports creative workflows like writing scripts, drafting post copy, and planning content weeks.
2 investors
Endogene is a biotech company focused on uterine biology, developing tools to improve the understanding, diagnosis, and treatment of uterine diseases.
2 investors
Endometrics is a molecular diagnostics company developing non-invasive tests for women's health that use menstrual blood as an organ-proximal liquid biopsy, with an initial focus on endometriosis. It combines tissue-derived biomarker discovery, bioinformatics, and at-home sample collection to enable molecular diagnostics for gynecologic diseases.
2 investors
Endra provides an AI-powered platform for MEP (mechanical, electrical, plumbing) and fire protection engineers to automate design, documentation, and compliance workflows within Autodesk Revit. The platform generates 2D/3D models, shop drawings, calculations, and compliance documentation for building systems across EU, UK, and US markets.
2 investors
Enduro develops synthetic biology technology for large-scale fermentation processes, helping bioproduction companies maintain high cell productivity and strain stability during bio-based manufacturing. The company provides genetic tools and RNA sequencing services to prevent production decline in cultivated cells across diverse bioproducts.
2 investors
Company whose formation and launch the LifeSci team supported.
2 investors
enGene is a genetic medicine company developing drug therapies across oncology, urology, and other therapeutic areas, with a focus on patient outcomes.
2 investors
Enoda develops synthetic cytokine receptors, called MIMICs, that link therapeutic "Signal 3" cytokine functions to controllable inputs to engineer cell therapies without systemic toxicity. It offers a platform and discovery screens to optimize CAR T cells, regulatory T cells, macrophages, and stem cells for autologous, allogenic, and in vivo cell therapy partners.
2 investors
En Plus One Bio develops synthesis and manufacturing technology for RNA therapeutics, focused on producing high-purity long RNA with higher cycle efficiencies and novel chemical modifications. It aims to expand the accessible RNA design space and manufacturing capacity for RNA-based drugs.
2 investors
Ensho is a biopharmaceutical company developing NSHO-101, an oral, selective small molecule Ξ±4Ξ²7 inhibitor intended as a once-daily treatment for patients with inflammatory bowel disease (IBD). The drug candidate, acquired from EA Pharma, is designed as an oral alternative to biologic therapies and as an anchor for oral combination therapy, and is currently in Phase 1 clinical development.
2 investors
Entelexo develops engineered exosome therapeutics for autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. The company uses a proprietary platform to design exosomes that communicate with multiple diseased cell types simultaneously, replacing traditional single-target treatments.
2 investors
Enterprise Therapeutics is a drug discovery company developing therapies for respiratory diseases such as cystic fibrosis, asthma, and COPD. Its research targets the underlying mechanisms of mucus congestion in the lungs to reduce lung infections and improve patient quality of life.
2 investors
Envirotainer provides temperature-controlled solutions for the pharmaceutical supply chain, serving healthcare providers and pharmaceutical distributors. The company offers tailored solutions across different stages of the pharmaceutical lifecycle.
2 investors